Cidara Therapeutics, Inc. CDTX
221.38 USD 0.00 (+0.00%)
Jan 8, 2026, 9:30 AM EST
221.38 Day range 221.38
52-week range unavailable
- YTD
- +0.22%
- 1 year
- +725.74%
Analyst view
Price target (mean) —
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.33 | -1.64 – -1.22 | -2.38 | +44.2% | 0 | 0.0% | 7 |
| Current quarter | -1.82 | -2.31 – -1.19 | -20.65 | +91.2% | 0 | -100.0% | 6 |
| Current quarter | -3.47 | -5.45 – -1.47 | -2.28 | -52.3% | 0 | -100.0% | 4 |
| Current quarter | -4.25 | -5.66 – -1.87 | -1.80 | -136.1% | 430.00K | 0.0% | 3 |
| Current quarter | -3.22 | -4.10 – -2.35 | -2.80 | -15.0% | 4.70M | 0.0% | 2 |
| Current quarter | -0.20 | -0.20 – -0.20 | 0.60 | -133.3% | 8.46M | -67.4% | 1 |
| Current quarter | -0.16 | -0.20 – -0.11 | 0.17 | -194.1% | 8.14M | -80.0% | 4 |
| Current quarter | -0.13 | -0.19 – -0.09 | -0.19 | +31.6% | 11.55M | +85.8% | 3 |
| Current quarter | -0.04 | -0.19 – 0.06 | -0.27 | +85.2% | 18.68M | +162.8% | 3 |
| Current quarter | 0.18 | 0.12 – 0.30 | -0.37 | +148.6% | 35.67M | +404.1% | 3 |
| Current quarter | -0.28 | -0.29 – -0.26 | 0.18 | -255.6% | 6.21M | 0.0% | 4 |
| Current quarter | -0.29 | -0.37 – -0.26 | -0.39 | +25.6% | 6.11M | +153.7% | 5 |
| Current quarter | -0.36 | -0.40 – -0.32 | -0.41 | +12.2% | 2.94M | +21.7% | 6 |
| Current quarter | -0.08 | -0.27 – 0.10 | -0.45 | +82.2% | 18.20M | 0.0% | 2 |
| Current quarter | -0.26 | -0.45 – -0.15 | -0.46 | +43.5% | 10.50M | +315.0% | 3 |
| Current quarter | -0.38 | -0.51 – -0.10 | 0.08 | -575.0% | 4.89M | -74.4% | 5 |
| Current quarter | -0.28 | -0.45 – -0.02 | -0.49 | +42.9% | 5.27M | 0.0% | 5 |
| Current quarter | -0.34 | -0.44 – -0.20 | -0.60 | +43.3% | 2.25M | 0.0% | 5 |
| Current quarter | -0.26 | -0.64 – 0.42 | -0.49 | +46.9% | 6.00M | 0.0% | 6 |
| Current quarter | -0.56 | -0.65 – -0.36 | -1.13 | +50.4% | 0 | 0.0% | 5 |
| Current quarter | -0.60 | -0.70 – -0.51 | -0.80 | +25.0% | 0 | 0.0% | 4 |
| Current quarter | -0.60 | -0.66 – -0.56 | -0.73 | +17.8% | 0 | 0.0% | 5 |
| Current quarter | -0.66 | -0.83 – -0.53 | -0.99 | +33.3% | 0 | 0.0% | 7 |
| Current quarter | -0.65 | -0.72 – -0.58 | -0.80 | +18.8% | 260.00K | 0.0% | 6 |
| Current quarter | -0.94 | -1.02 – -0.81 | -0.88 | -6.8% | 210.00K | 0.0% | 9 |
| Current quarter | -0.88 | -0.96 – -0.76 | -0.85 | -3.5% | 0 | 0.0% | 7 |
| Next quarter | -1.64 | -1.64 – -1.64 | -1.66 | +1.2% | 0 | 0.0% | 1 |
| Current year | -8.68 | -9.16 – -7.94 | -26.82 | +67.6% | 0 | -100.0% | 4 |
| Current year | -22.94 | -27.35 – -18.89 | -5.20 | -341.1% | 6.03M | -90.6% | 4 |
| Current year | -0.31 | -0.36 – -0.28 | -0.43 | +27.9% | 57.85M | -10.0% | 3 |
| Current year | -0.42 | -0.52 – -0.29 | -0.81 | +48.1% | 62.02M | +25.1% | 3 |
| Current year | -0.88 | -0.93 – -0.81 | -1.80 | +51.1% | 46.64M | +286.5% | 6 |
| Current year | -1.54 | -1.73 – -1.44 | -1.41 | -9.2% | 18.53M | -11.4% | 4 |
| Current year | -1.39 | -1.61 – -1.17 | -2.76 | +49.6% | 21.82M | 0.0% | 6 |
| Current year | -2.96 | -3.12 – -2.81 | -3.18 | +6.9% | 0 | 0.0% | 4 |
| Current year | -3.29 | -3.45 – -3.11 | -3.32 | +0.9% | 210.00K | 0.0% | 7 |
| Next year | -7.21 | -10.06 – -5.02 | -8.68 | +16.9% | 11.80M | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2025 | Guggenheim | Downgrade | Buy | Neutral |
| Nov 14, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Nov 14, 2025 | Needham | Downgrade | Buy | Hold |
| Nov 7, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 7, 2025 | Needham | Maintained | Buy | Buy |
| Oct 21, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 16, 2025 | Morgan Stanley | Initiated | — | Overweight |
| Oct 10, 2025 | JP Morgan | Initiated | — | Overweight |
| Oct 9, 2025 | WBB Securities | Maintained | Strong Buy | Strong Buy |
| Oct 9, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 3, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Sep 26, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 25, 2025 | Guggenheim | Maintained | Buy | Buy |
| Sep 24, 2025 | Needham | Maintained | Buy | Buy |
| Sep 24, 2025 | WBB Securities | Reiterated | Strong Buy | Strong Buy |
| Sep 22, 2025 | WBB Securities | Maintained | Strong Buy | Strong Buy |
| Aug 8, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Aug 8, 2025 | Needham | Maintained | Buy | Buy |
| Aug 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 30, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Jun 24, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Jun 24, 2025 | Guggenheim | Maintained | Buy | Buy |
| Jun 24, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 23, 2025 | WBB Securities | Reiterated | Strong Buy | Strong Buy |
| Jun 23, 2025 | Needham | Maintained | Buy | Buy |
| Jun 10, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 4, 2025 | Needham | Maintained | Buy | Buy |
| Jun 2, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 27, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 23, 2025 | RBC Capital | Maintained | Outperform | Outperform |